MX363389B - Composicion farmaceutica que comprende ivabradina amorfa. - Google Patents

Composicion farmaceutica que comprende ivabradina amorfa.

Info

Publication number
MX363389B
MX363389B MX2016007682A MX2016007682A MX363389B MX 363389 B MX363389 B MX 363389B MX 2016007682 A MX2016007682 A MX 2016007682A MX 2016007682 A MX2016007682 A MX 2016007682A MX 363389 B MX363389 B MX 363389B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
ivabradine
pharmaceutically acceptable
amorphous ivabradine
amorphous
Prior art date
Application number
MX2016007682A
Other languages
English (en)
Other versions
MX2016007682A (es
Inventor
Álvarez Fernández Lisardo
Keltjens Rolf
Theodorus Henricus Eupen Van Jacobus
Murpani Deepak
Garcia Jimenez Sonia
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of MX2016007682A publication Critical patent/MX2016007682A/es
Publication of MX363389B publication Critical patent/MX363389B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende un complejo de inclusión de ivabradina o una sal farmacéuticamente aceptable de la misma, en forma amorfa en una ß-ciclodextrina no sustituida y uno o más excipientes farmacéuticamente aceptables; la invención se relaciona adicionalmente con el uso de la composición como un medicamento, particularmente en el tratamiento de angina de pecho estable e insuficiencia cardíaca crónica.
MX2016007682A 2013-12-12 2014-10-21 Composicion farmaceutica que comprende ivabradina amorfa. MX363389B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2013076429 2013-12-12
PCT/EP2014/072524 WO2015001133A1 (en) 2013-12-12 2014-10-21 Pharmaceutical composition comprising amorphous ivabradine

Publications (2)

Publication Number Publication Date
MX2016007682A MX2016007682A (es) 2016-09-09
MX363389B true MX363389B (es) 2019-03-20

Family

ID=51845386

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007682A MX363389B (es) 2013-12-12 2014-10-21 Composicion farmaceutica que comprende ivabradina amorfa.

Country Status (3)

Country Link
ES (1) ES2672472T3 (es)
MX (1) MX363389B (es)
WO (1) WO2015001133A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170100408A1 (en) * 2014-03-27 2017-04-13 Laboratorio Chimico Internazionale S.P.A. Ivabradine adsorbates
GB201621771D0 (en) * 2016-12-20 2017-02-01 Biogena (A P I) Ltd New salts of compounds and uses thereof
TR201703066A2 (tr) * 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282B1 (en) * 2017-02-28 2025-10-01 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
CN109875969B (zh) * 2019-03-19 2021-02-09 扬子江药业集团北京海燕药业有限公司 一种稳定的盐酸伊伐布雷定片剂及其制备方法
CN115770248B (zh) * 2022-12-07 2023-08-04 郑州大学第一附属医院 一种盐酸伊伐布雷定制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
PL1793862T3 (pl) * 2004-08-02 2011-08-31 Chiesi Farm Spa Sposób wytwarzania związku włączeniowego piroksykam:beta-cyklodekstyna
FR2882556B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
KR101478855B1 (ko) 2007-05-30 2015-01-02 인드-스위프트 래버러토리즈 리미티드 이바브라딘 히드로클로라이드 및 그의 다형태의 제조방법
CN101597261A (zh) 2008-06-06 2009-12-09 北京深蓝海生物医药科技有限公司 无定形盐酸伊伐布雷定
CN101463008A (zh) 2009-01-11 2009-06-24 山东鲁抗辰欣药业有限公司 盐酸伊伐布雷定无定型物及其制备方法
CN101559228B (zh) * 2009-06-01 2011-05-18 石药集团欧意药业有限公司 一种治疗高脂血症合并慢性稳定型心绞痛的药物组合物
SI23290A (sl) 2010-02-12 2011-08-31 Krka D.D., Novo Mesto Nove oblike ivabradin hidroklorida
US20130116239A1 (en) 2010-06-14 2013-05-09 ratiopharm GnbH Ivabradine-containing pharmaceutical composition with modified release
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2014161131A1 (en) * 2013-04-01 2014-10-09 Arissa Pharma PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
CN103393611B (zh) * 2013-08-06 2015-08-19 南京正大天晴制药有限公司 一种盐酸伊伐布雷定片剂及其制备方法

Also Published As

Publication number Publication date
ES2672472T3 (es) 2018-06-14
WO2015001133A1 (en) 2015-01-08
MX2016007682A (es) 2016-09-09

Similar Documents

Publication Publication Date Title
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
PH12015501096A1 (en) Composition for immediate and extended release
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
PH12015502755A1 (en) Insulin glargine / lixisenatide fixed ratio formulation
MX363389B (es) Composicion farmaceutica que comprende ivabradina amorfa.
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2016001422A (es) Composicion farmaceutica de fingolimod.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
IN2013MU02015A (es)
UA105513C2 (uk) Лікарська форма уповільненого вивільнення глюкозаміну
IN2013MU03656A (es)
UA114396C2 (uk) Фармацевтична композиція з антиішемічною та антигіпертензивною дією